Comparison of Clopidogrel and Ticagrelor on Microvascular Dysfunction in ST-Segment Elevation Myocardial Infarction
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
Ticagrelor is a non-thienophyridine, direct P2Y12 blocker that is more potent than
clopidogrel and is associated with less interindividual variability. In the PLATO trial, it
was found to be superior to clopidogrel with respect to cardiovascular outcomes and total
mortality without increasing the risk of bleedings.
More potent and reversible receptor bindings are possible explanation for the superior
outcomes. Beside the potent effect on inhibition of antiplatelet function, ticagrelor has
previously been demonstrated to increase adenosine levels by inhibiting adenosine re-uptake
in tissue level and can induce adenosine triphosphate (ATP) release from human red cells,
which both stimulate vasodilation of in red blood cells.